JP7376901B2 - 修飾金属ナノ粒子及び医薬組成物 - Google Patents

修飾金属ナノ粒子及び医薬組成物 Download PDF

Info

Publication number
JP7376901B2
JP7376901B2 JP2018213201A JP2018213201A JP7376901B2 JP 7376901 B2 JP7376901 B2 JP 7376901B2 JP 2018213201 A JP2018213201 A JP 2018213201A JP 2018213201 A JP2018213201 A JP 2018213201A JP 7376901 B2 JP7376901 B2 JP 7376901B2
Authority
JP
Japan
Prior art keywords
nanoparticles
modified
metal
metal nanoparticles
gold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018213201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019090111A (ja
JP2019090111A5 (enExample
Inventor
拓矢 山本
ホセ エンリコ キンサート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Original Assignee
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC filed Critical Hokkaido University NUC
Publication of JP2019090111A publication Critical patent/JP2019090111A/ja
Publication of JP2019090111A5 publication Critical patent/JP2019090111A5/ja
Priority to JP2023130727A priority Critical patent/JP7557902B2/ja
Application granted granted Critical
Publication of JP7376901B2 publication Critical patent/JP7376901B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Powder Metallurgy (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
JP2018213201A 2017-11-13 2018-11-13 修飾金属ナノ粒子及び医薬組成物 Active JP7376901B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023130727A JP7557902B2 (ja) 2017-11-13 2023-08-10 修飾金属ナノ粒子及び医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017218620 2017-11-13
JP2017218620 2017-11-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023130727A Division JP7557902B2 (ja) 2017-11-13 2023-08-10 修飾金属ナノ粒子及び医薬組成物

Publications (3)

Publication Number Publication Date
JP2019090111A JP2019090111A (ja) 2019-06-13
JP2019090111A5 JP2019090111A5 (enExample) 2022-04-01
JP7376901B2 true JP7376901B2 (ja) 2023-11-09

Family

ID=66431157

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018213201A Active JP7376901B2 (ja) 2017-11-13 2018-11-13 修飾金属ナノ粒子及び医薬組成物
JP2023130727A Active JP7557902B2 (ja) 2017-11-13 2023-08-10 修飾金属ナノ粒子及び医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023130727A Active JP7557902B2 (ja) 2017-11-13 2023-08-10 修飾金属ナノ粒子及び医薬組成物

Country Status (2)

Country Link
US (1) US11116793B2 (enExample)
JP (2) JP7376901B2 (enExample)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082561A1 (ja) 2004-02-27 2005-09-09 Sanc Salaam Corporation コロイダル金属
JP2007051319A (ja) 2005-08-17 2007-03-01 Nippon Telegr & Teleph Corp <Ntt> 金属ナノ微粒子複合体およびその製造方法、金属ナノ微粒子複合体凝集物およびその製造方法
JP2011026665A (ja) 2009-07-27 2011-02-10 National Institute For Materials Science 樹枝状部分を有する金属ナノ粒子及びその製法
WO2011071167A1 (ja) 2009-12-11 2011-06-16 学校法人東京理科大学 金－銀コアシェルナノロッド粒子及びその製造方法
JP2012532847A (ja) 2009-07-10 2012-12-20 ナノビオティックス 金属ナノ粒子、その調製および使用
JP2013504692A (ja) 2009-09-14 2013-02-07 ハンファ ケミカル コーポレーション 水溶性ナノ粒子及びその分散液を製造する方法
JP2014189821A (ja) 2013-03-26 2014-10-06 Shinshu Univ 金属ナノ粒子の形成方法および金属ナノ粒子材料
JP2016527204A (ja) 2013-06-20 2016-09-08 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 医療診断に使用するための組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4111638B2 (ja) 1999-09-14 2008-07-02 独立行政法人科学技術振興機構 金コロイド粒子とその調製方法並びに金イオンの選択的捕捉方法
CA2473429A1 (en) 2003-07-09 2005-01-09 National Research Council Of Canada Process for producing gold nanoparticles
WO2010083041A1 (en) * 2009-01-15 2010-07-22 Cornell University Nanoparticle organic hybrid materials (nohms)
US8226985B2 (en) * 2010-01-28 2012-07-24 International Business Machines Corporation Surface modified nanoparticles, methods of their preparation, and uses thereof for gene and drug delivery
US8795924B2 (en) * 2012-09-12 2014-08-05 GM Global Technology Operations LLC Crown ether containing PEM electrode
WO2014066793A1 (en) * 2012-10-26 2014-05-01 Board Of Regents, The University Of Texas System Polymer coated nanoparticles

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082561A1 (ja) 2004-02-27 2005-09-09 Sanc Salaam Corporation コロイダル金属
JP2007051319A (ja) 2005-08-17 2007-03-01 Nippon Telegr & Teleph Corp <Ntt> 金属ナノ微粒子複合体およびその製造方法、金属ナノ微粒子複合体凝集物およびその製造方法
JP2012532847A (ja) 2009-07-10 2012-12-20 ナノビオティックス 金属ナノ粒子、その調製および使用
JP2011026665A (ja) 2009-07-27 2011-02-10 National Institute For Materials Science 樹枝状部分を有する金属ナノ粒子及びその製法
JP2013504692A (ja) 2009-09-14 2013-02-07 ハンファ ケミカル コーポレーション 水溶性ナノ粒子及びその分散液を製造する方法
WO2011071167A1 (ja) 2009-12-11 2011-06-16 学校法人東京理科大学 金－銀コアシェルナノロッド粒子及びその製造方法
JP2014189821A (ja) 2013-03-26 2014-10-06 Shinshu Univ 金属ナノ粒子の形成方法および金属ナノ粒子材料
JP2016527204A (ja) 2013-06-20 2016-09-08 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 医療診断に使用するための組成物および方法

Also Published As

Publication number Publication date
JP7557902B2 (ja) 2024-09-30
JP2019090111A (ja) 2019-06-13
JP2023159222A (ja) 2023-10-31
US11116793B2 (en) 2021-09-14
US20190142865A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
Ma et al. Metal–organic frameworks towards bio-medical applications
Hu et al. Real-time monitoring of pH-responsive drug release using a metal-phenolic network-functionalized upconversion nanoconstruct
Zhou et al. Nanoscaled metal‐organic frameworks for biosensing, imaging, and cancer therapy
Jafari et al. pH-sensitive biosystem based on laponite RD/chitosan/polyvinyl alcohol hydrogels for controlled delivery of curcumin to breast cancer cells
CN105199718B (zh) 一种红色荧光金/铜纳米团簇合金及其制备方法和应用
Wang et al. pH-responsive glycol chitosan-cross-linked carboxymethyl-β-cyclodextrin nanoparticles for controlled release of anticancer drugs
Belyaev et al. Laser‐Synthesized Germanium Nanoparticles as Biodegradable Material for Near‐Infrared Photoacoustic Imaging and Cancer Phototherapy
Dutta et al. Two-photon excitable membrane targeting polyphenolic carbon dots for long-term imaging and pH-responsive chemotherapeutic drug delivery for synergistic tumor therapy
Patel et al. Doxorubicin-conjugated platinum theranostic nanoparticles induce apoptosis via inhibition of a cell survival (PI3K/AKT) signaling pathway in human breast cancer cells
Kalva et al. Aggregation-induced emission-active hyperbranched polymer-based nanoparticles and their biological imaging applications
Poorhossein et al. Designing a multifunctional nanoplatform based on PEGylated cobalt ferrite magnetic nanoparticles containing capecitabine for cancer theranostics
CN104535541A (zh) 一种检测细胞糖基化水平的方法
Babaei et al. Harnessing curcumin in a multifunctional biodegradable metal-organic framework (bio-MOF) for targeted colorectal cancer theranostics
Chen et al. Erythrocyte membrane-camouflaged Prussian blue nanocomplexes for combinational therapy of triple-negative breast cancer
CN111909495B (zh) 一种用于sers检测的柔性膜状材料及其制备方法
Yang et al. Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles
Shukla et al. Iota carrageenan linked barium ion nanoparticle synthesis for the selective targeted imaging and inhibition of cancer cells
CN111588690B (zh) 一种响应性透明质酸荧光纳米凝胶、制备方法和应用
Chen et al. Theranostic system based on NaY (Mn) F 4: Yb/Er upconversion nanoparticles with multi-drug resistance reversing ability
JP7376901B2 (ja) 修飾金属ナノ粒子及び医薬組成物
He et al. Targeted gold nanoparticles for ovarian cancer
Ban et al. Intramolecular Copper‐Containing Hyperbranched Polytriazole Assemblies for Label‐Free Cellular Bioimaging and Redox‐Triggered Copper Complex Delivery
Yang et al. Mesoporous silica nanoparticles loaded with fluorescent coumarin-5-fluorouracil conjugates as mitochondrial-targeting theranostic probes for tumor cells
CN106176620A (zh) 一种石墨烯药物缓释微球及其制备方法
Qin et al. Confined growth of multiple gold nanorices in dual-mesoporous silica nanospheres for improved computed tomography imaging and photothermal therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181129

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20190219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231020

R150 Certificate of patent or registration of utility model

Ref document number: 7376901

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150